Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme | withdrawn | Phase 3 | 323 | Xenova BiomedixINDUSTRY | 2 | Jan 7, 2009 | clinicaltrials |
| NCT00517218 | This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) | withdrawn | Phase 3 | — | Genta IncorporatedINDUSTRY | 0 | Feb 11, 2008 |
| clinicaltrials |
| NCT00226668 | XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema | withdrawn | Phase 3 | 120 | Celtic Pharma Development ServicesINDUSTRY | 2 | Jan 3, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jan 7, 2009source: clinicaltrials